Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CCTx 001

Next Previous
X
Search
Drug Profile

CCTx 001

Alternative Names: CCTx-001

Latest Information Update: 17 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advesya
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Interleukin-1 receptor accessory protein inhibitors; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 13 Jun 2024 Pharmacodynamics data from a preclinical trial in Acute myeloid leukemia presented at the 29th Congress of the European Haematology Association (EHA-2024)
  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Amyloid cell leukemia presented at the 115th Annual Meeting of the American Association for Cancer Research Session (AACR-2024)
  • 29 Feb 2024 Advesya plans a phase I/II trial for Acute myeloid leukaemia (Second-line therapy or greater) in France, Germany, Spain, Sweden (Parenteral, Infusion), in Q2 2024 (NCT06281847)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top